GENE ONLINE|News &
Opinion
Blog

[Illustrations] 2026 Oncology Crossroads: Enhertu’s HER2 Tumor‑Agnostic Expansion, Front‑Line ADC Adoption, and the Clinical Proving Ground for Next‑Gen Mechanisms

by Oscar Wu
Share To
2026 Oncology Crossroads: Enhertu’s HER2 Tumor‑Agnostic Expansion, Front‑Line ADC Adoption, and the Clinical Proving Ground for Next‑Gen Mechanisms"]
2026 Oncology crossroads divided into cytotoxic regimens and smart chemotherapy. (Design: Oscar Wu)
In the 2026 “clearing year” environment that is forcing AI platforms and radiopharma supply chains to prove themselves, antibody-drug conjugates (ADCs) are being positioned as …

[Illustrations] 2026 Oncology Crossroads: Enhertu’s HER2 Tumor‑Agnostic Expansion, Front‑Line ADC Adoption, and the Clinical Proving Ground for Next‑Gen Mechanisms Read More »

GO Prime with only $1.49 now

LATEST
Founders Metals Joins GDXJ Index and Begins Drilling at Antino North Project
2026-03-17
Aclarion to Present Financial Updates and 2026 Catalysts at 38th Annual ROTH Conference
2026-03-17
Aeroméxico Directors and Executives Acquire Company Shares Through Individual Investment Decisions
2026-03-17
Fury Gold Mines Reports 11.74 g/t Gold Over 6.63 Meters in Eau Claire Phase 2 Drilling Campaign
2026-03-17
Beam Global Receives Record $1.7 Million in Weekly Orders for Smart Cities Infrastructure Products
2026-03-17
Study Finds Nearly Half of Physicians Concerned About AI Accuracy in Healthcare
2026-03-17
Huize Holding Limited to Release 2025 Second Half and Full Year Financial Results on March 27, 2026
2026-03-17
Scroll to Top